ライフサイエンスコーパス: immunosuppressed

1 focus on these features in patients who are immunosuppressed.

2 sh also developed in the monkey that was not immunosuppressed.

3 genic, particularly when infected people are immunosuppressed.

4 illness and opportunistic infection for the immunosuppressed.

5 s is required for the duration of time while immunosuppressed.

6 kidney transplant recipients who are already immunosuppressed.

7 nts are asymptomatic, despite being severely immunosuppressed.

8 th symptomatic HIV infection if not severely immunosuppressed.

9 with SVV, and 5 months later, 4 monkeys were immunosuppressed; 1 monkey was not immunosuppressed but

10 Most patients with 10 or more CSCCs were immunosuppressed (15 of 19 [78.9%]).

11 patients had mNGS testing; the majority were immunosuppressed (62%).

12 ant recipients (average age = 54 years, time immunosuppressed = 8.9 years), 135 (27%) had basal cell

13 , monocytes from lungs of TBI + Sp mice were immunosuppressed acutely after traumatic brain injury an

14 Among severely immunosuppressed adults with HIV infection who had not p

15 ng children and more extensive infections in immunosuppressed adults, has constrained our understandi

16 s in young children and severe infections in immunosuppressed adults.

17 nary artery followed by reperfusion and were immunosuppressed after MI with cyclosporine and methylpr

18 Four patients were immunosuppressed after solid organ transplant and all we

19 aths occurred among patients who were obese, immunosuppressed, aged >65 years, or received oseltamivi

20 Cancer patients are frequently immunosuppressed and at risk for a wide range of opportu

21 n-years and 0.43 per 100 person-years in the immunosuppressed and corticosteroid only groups, respect

22 re human skin cancer that most often affects immunosuppressed and elderly persons.

23 C gattii, with infections occurring in both immunosuppressed and immunocompetent individuals.

24 in the incidence of vascular events between immunosuppressed and immunocompetent patients.

25 eactivation of HHV-6A is frequent within the immunosuppressed and immunocompromised populations and r

26 combination oral antiviral regimens in other immunosuppressed and interferon refractory HCV patients.

27 d-organ disease that results in death in the immunosuppressed and is a leading cause of birth defects

28 ay be lower than previously reported both in immunosuppressed and nonimmunosuppressed patients.

29 andemic, as many of these individuals may be immunosuppressed and of older age.

30 nto adenosine, endorses the generation of an immunosuppressed and pro-angiogenic niche within the tum

31 any patients who survive acute sepsis become immunosuppressed and succumb to opportunistic infections

32 his risk, particularly in young children and immunosuppressed and/or critically ill patients, who may

33 BV is more prevalent in women who are immunosuppressed, and several risk factors for the devel

34 Using xenogeneic (human) cells in immunosuppressed animals with acute ischemic heart disea

35 ntibody and found that pretreatment, even in immunosuppressed animals, limited infection.

36 ing into the central nervous system (CNS) in immunosuppressed animals.

37 he same TSO treatment exacerbates colitis in immunosuppressed animals.

38 safety of TSO therapy in immunocompetent and immunosuppressed animals.

39 nt, which is enriched with dysfunctional and immunosuppressed antigen-presenting cells (APCs).

40 In this immunosuppressed background, cellular defenses provide a

41 ich these antigens are released is typically immunosuppressed, blunting the ability to initiate immun

42 keys were immunosuppressed; 1 monkey was not immunosuppressed but was subjected to the stress of tran

43 nd such infections may be more severe in the immunosuppressed), but there is only anecdotal evidence

44 We examined whether AM are immunosuppressed by LT.

45 Immunosuppressed cases were further subcategorized into

46 ered from a case of fatal encephalitis in an immunosuppressed child.

47 fied a related virus in the stool of another immunosuppressed child.

48 he short-term COVID-19 clinical course in an immunosuppressed child.

49 is known about the effect of this disease in immunosuppressed children with renal transplantation (RT

50 tic tool for immunoreconstitution of heavily immunosuppressed CLL patients and, in combination with b

51 diabetes, underlying lung disease, smoking, immunosuppressed condition, and baseline disease severit

52 severe direct and indirect pathologies under immunosuppressed conditions and is the leading cause of

53 associated with several human diseases under immunosuppressed conditions.

54 ion, reactivation of latent infections in an immunosuppressed context, or possible de-novo infection

55 previously reported incidence of PCP in all immunosuppressed dermatologic patients (0.1% vs 1.3%; ch

56 r risk of PCP than the general population of immunosuppressed dermatology patients.

57 Recipients were immunosuppressed either with cyclosporine A (CsA, 1.5 mg

58 Allografts were immunosuppressed either with cyclosporine or with cyclos

59 e hematopoietic cell transplants are usually immunosuppressed for extended periods, and infection wit

60 Treatment of T cells from immunosuppressed glioblastoma patients with miR-124 indu

61 the corticosteroid treatment-only group, the immunosuppressed group was at an increased risk of any m

62 In the immunosuppressed group, the most common malignancies wer

63 These immunosuppressed hamster models provide researchers with

64 Disease was prolonged in transiently immunosuppressed hamsters and was uniformly lethal in RA

65 Here, we demonstrate that immunosuppressed hamsters are susceptible to low doses o

66 Immunosuppressed hamsters infected with SNV have a mean

67 rst report that details vismodegib use in an immunosuppressed heart transplant patient receiving cycl

68 esistance in intensive care units, expanding immunosuppressed host populations, and public health cri

69 lted from incomplete viral suppression in an immunosuppressed host with a high viral load.

70 TSPyV) occur during primary infection of the immunosuppressed host.

71 In immunosuppressed hosts with a high organism burden, orga

72 Most cases occur in immunosuppressed hosts, including patients with HIV/AIDS

73 Here, in immunosuppressed hosts, we uncover rare naturally arisin

74 anting further analysis of virus subtypes in immunosuppressed hosts.

75 ortunistic infection, especially in severely immunosuppressed hosts.

76 K variants arising in immunocompetent versus immunosuppressed hosts; and 2) by investigating the effe

77 ymphoma (PCNSL) risk is greatly increased in immunosuppressed human immunodeficiency virus-infected p

78 adjectives such as immune, immunocompetent, immunosuppressed, immunocompromised, or immunologically

79 All patients were immunosuppressed in 18 of 24 (75%) reports with availabl

80 ble morbidity and mortality, particularly in immunosuppressed individuals ('carcinomatous catastrophy

81 y reactivation of JC polyomavirus (JCPyV) in immunosuppressed individuals and lytic infection by neur

82 ocytes and astrocytes in the white matter of immunosuppressed individuals and was almost always fatal

83 Although immunosuppressed individuals are thought to be at an inc

84 The extent to which iatrogenically-immunosuppressed individuals benefit from indirect effec

85 However, infection in immunocompromised or immunosuppressed individuals can result in malignant B c

86 s demonstrate that protective vaccination of immunosuppressed individuals is possible, provided that

87 underway to determine whether populations of immunosuppressed individuals might ultimately benefit fr

88 ion of illness associated with infections in immunosuppressed individuals put close human immunodefic

89 It has a higher incidence in immunosuppressed individuals such as organ transplant re

90 es significant urinary tract pathogenesis in immunosuppressed individuals, including kidney and bone

91 AdV) infections are an increasing threat for immunosuppressed individuals, particularly those who hav

92 ers, typically of B cell origin, observed in immunosuppressed individuals, such as posttransplant or

93 n in both immunocompetent and iatrogenically-immunosuppressed individuals, underscoring the benefit o

94 In immunosuppressed individuals, VE against zoster was 0.37

95 clinical outcomes are typically observed in immunosuppressed individuals, with the most extreme case

96 fections occur in immunocompetent as well as immunosuppressed individuals.

97 cause severe diseases, including cancers in immunosuppressed individuals.

98 lammatory diseases and cancer, especially in immunosuppressed individuals.

99 sive multifocal leukoencephalopathy (PML) in immunosuppressed individuals.

100 l leukoencephalopathy (PML) in the brains of immunosuppressed individuals.

101 associated with novel pathogenicity in some immunosuppressed individuals.

102 to an increase in the world's population of immunosuppressed individuals.

103 matic but can lead to severe consequences in immunosuppressed individuals.

104 e chronic disease, and threaten the lives of immunosuppressed individuals.

105 Pneumonia is commonly diagnosed in immunosuppressed individuals.

106 are particularly numerous and aggressive in immunosuppressed individuals.

107 ulmonary sources, presenting as pneumonia in immunosuppressed individuals.

108 ainst chronic gamma-herpesvirus infection in immunosuppressed individuals.

109 idity and mortality in immunocompromised and immunosuppressed individuals.

110 ssociated with invasive fungal infections in immunosuppressed individuals.

111 ssion with higher levels being found in more immunosuppressed individuals.

112 gnificant cause of morbidity in neonates and immunosuppressed individuals.

113 which is a major opportunistic infection in immunosuppressed individuals.

114 n and effector functions in hospitalized and immunosuppressed individuals.

115 is pneumonia (PCP) is a common problem among immunosuppressed individuals.

116 We tested whether the motility of hCSCs in immunosuppressed infarcted animals is controlled by the

117 Atrioventricular blocked dogs were immunosuppressed, instrumented with VVI pacemakers, and

118 nced pulmonary M1 macrophage polarization in immunosuppressed (IS) hosts, but an M2 predominant respo

119 studying virus replication and apoptosis in immunosuppressed (IS) TNF-alpha(-/-) mice.

120 Our findings indicate that immunosuppressed kidney transplant recipients admitted t

121 that naive mice (i.e., not pharmacologically immunosuppressed) lacking the beta-glucan receptor Decti

122 owing to treatment-limiting toxic effects in immunosuppressed liver-transplant recipients.

123 0 neuronal infection occurs spontaneously in immunosuppressed macaques, we analyzed archival brain sp

124 pontaneous SV40 neuronal infection occurs in immunosuppressed macaques, which parallels JC virus-neur

125 Immunosuppressed male Sprague-Dawley rats were exposed t

126 is to understand in vivo efficacy within the immunosuppressed malignant ascites tissue microenvironme

127 n decisions for a pregnant woman, 73% for an immunosuppressed man, and 49% for an 8-month-old infant.

128 activity, decreased osteoblast function, and immunosuppressed marrow microenvironment, which deregula

129 s protein Asp f3 protected cortisone acetate-immunosuppressed mice from experimentally induced pulmon

130 evels of ID4 produced enlarged xenografts in immunosuppressed mice that were better vascularized than

131 htly, but significantly reduced mortality in immunosuppressed mice, but was unable to reduce hypoxia

132 inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the i

133 d iron acquisition in vitro and virulence in immunosuppressed mice.

134 ce, and the parasites did not recur in these immunosuppressed mice.

135 al, syngeneic mice but grew progressively in immunosuppressed mice.

136 VKAs decrease human HSC engraftment in immunosuppressed mice.

137 g protein, contributes to the creation of an immunosuppressed microenvironment at sites of tumor grow

138 de for NRAS+ melanoma suggests it has a more immunosuppressed microenvironment, which may affect its

139 growth and to maintaining a pro-tumorigenic, immunosuppressed microenvironment.

140 mellonella model and also in a persistently immunosuppressed murine model of invasive aspergillosis

141 apid appearance of de novo alloantibodies in immunosuppressed nonsensitized recipients and absence of

142 wth delay in a syngeneic model (C3H) but not immunosuppressed (Nu/Nu) squamous cell carcinoma tumor-b

143 There were 10,316 (43.0%) immunosuppressed or immunocompromised patients, 4,135 (2

144 Cyclophosphamide (CyP) immunosuppressed or RAG2 knockout (KO) hamsters were exp

145 ood pathogen that may cause acute disease in immunosuppressed or splenectomized dogs.

146 IPV, and who would not have any contact with immunosuppressed or unvaccinated people for the duration

147 procedures and HTLV-1 disease association in immunosuppressed organ recipients were analyzed.

148 umenting the use and safety of vismodegib in immunosuppressed organ transplant patients.

149 is an emerging pathogen that reactivates in immunosuppressed organ transplant patients.

150 With a growing immunosuppressed organ transplant population at high ris

151 nts with acute HEV infection, 18 HEV-exposed immunosuppressed organ-transplant recipients (8 with chr

152 ere exposed to P. jiroveci by cohousing with immunosuppressed, P. jiroveci-colonized macaques in two

153 roach to survey the viral population from an immunosuppressed patient infected with H1N1/2009 influen

154 The increase in immunosuppressed patient populations has correlated with

155 s of survival, even in the most persistently immunosuppressed patient receiving chemotherapy and/or o

156 trapping was performed on the farm where the immunosuppressed patient was employed.

157 The approach to the immunosuppressed patient with progressive neurologic dec

158 roteins of both drugs during treatment of an immunosuppressed patient with relapsing babesiosis.

159 nary tract infections (UTIs) are frequent in immunosuppressed patients after kidney transplantation a

160 emonstration of the immune control of CMV in immunosuppressed patients and emphasize the effectivenes

161 betaherpesvirus, can cause severe disease in immunosuppressed patients and following congenital infec

162 be challenging because of its prevalence in immunosuppressed patients and its unique vascular and in

163 alitis (CM) is a major cause of mortality in immunosuppressed patients and previously healthy individ

164 leading cause of morbidity and mortality in immunosuppressed patients and treatment outcomes using o

165 ow to monitor immune response to vaccines in immunosuppressed patients and when to optimally immunize

166 Immunosuppressed patients are at risk for developing Eps

167 Immunosuppressed patients at high risk for invasive fung

168 s rarely caused acute morbidity, but in some immunosuppressed patients became persistent.

169 ent (QI) strategy to increase the numbers of immunosuppressed patients being kept up-to-date with pne

170 Immunosuppressed patients had an odds ratio of 1.94 of h

171 Immunosuppressed patients had significantly higher JCV D

172 major cause of life-threatening pneumonia in immunosuppressed patients including transplant recipient

173 Recently, drug resistance was reported in immunosuppressed patients infected with the 2009 pandemi

174 reliable biomarkers for strongyloidiasis in immunosuppressed patients is critical for the prevention

175 cal implications of tick-borne infections in immunosuppressed patients living in tick-endemic areas i

176 pediatric hospital with a high proportion of immunosuppressed patients nursed in isolation.

177 BKV reactivation in immunosuppressed patients or renal transplant patients i

178 se, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant

179 Immunosuppressed patients were less likely to receive ea

180 Immunosuppressed patients were treated with antimetaboli

181 ep vein thrombosis exclusively afflicted the immunosuppressed patients whereas arteritis was restrict

182 rs for developing severe disease, but so far immunosuppressed patients who are listed as high-risk pa

183 h may have important implications for use in immunosuppressed patients with cancer.

184 Histoplasmosis should be considered in immunosuppressed patients with fever, chills, abdominal

185 treatment occurred predominantly in severely immunosuppressed patients with heavy prior micafungin ex

186 Study of viral variants isolated from immunosuppressed patients with long-term norovirus infec

187 neurovirulence and in cerebrospinal fluid of immunosuppressed patients with multiple sclerosis, those

188 in a dramatic increase in the population of immunosuppressed patients with opportunistic, life-threa

189 Immunosuppressed patients with solid organ transplants h

190 ins or other organs of healthy people and in immunosuppressed patients without PML has been a matter

191 ection-is increased by more than 100-fold in immunosuppressed patients(2-4).

192 immune-mediated tumor control in chronically immunosuppressed patients, and begins to address the fea

193 tes to the development of B cell lymphoma in immunosuppressed patients, and may exacerbate flares of

194 a major cause of morbidity and mortality in immunosuppressed patients, and optimal diagnostic criter

195 clinical model for B cell lymphomagenesis in immunosuppressed patients, and validate a new therapeuti

196 Renal transplant recipients (RTRs), as all immunosuppressed patients, are at increased risk of reac

197 ty against invading pathogens, especially in immunosuppressed patients, but they also mediate graft l

198 neumocystis remains an important pathogen of immunosuppressed patients, causing a potentially life-th

199 antibiotics especially for the treatment of immunosuppressed patients, for those undergoing chemothe

200 In immunosuppressed patients, HCMV can remain relatively st

201 , which causes life-threatening pneumonia in immunosuppressed patients, remains poorly defined.

202 (CMV) infection is a serious complication in immunosuppressed patients, specifically transplant recip

203 very useful for studying clusters of PCP in immunosuppressed patients, to determine whether there is

204 ry, and central nervous system infections in immunosuppressed patients, was identified as the cause o

205 2019 (COVID-19)] poses unique challenges for immunosuppressed patients.

206 notype 3, which causes chronic infections in immunosuppressed patients.

207 NA response occurs during CMV replication in immunosuppressed patients.

208 osttransplant lymphoproliferative disease in immunosuppressed patients.

209 ) causes multicentric Castleman's disease in immunosuppressed patients.

210 y in patients with congenital infections and immunosuppressed patients.

211 mportant cause of morbidity and mortality in immunosuppressed patients.

212 aks and treat chronic norovirus infection in immunosuppressed patients.

213 olling active WNV infection, particularly in immunosuppressed patients.

214 ines suggest surveillance for HBV markers in immunosuppressed patients.

215 ght may contribute to skin carcinogenesis in immunosuppressed patients.

216 d as a possible cause of severe pneumonia in immunosuppressed patients.

217 ratory fungus that causes pneumonia (PcP) in immunosuppressed patients.

218 can cause devastating morbidity and death in immunosuppressed patients.

219 onsiderations in antifungal immunotherapy in immunosuppressed patients.

220 ich parallels JC virus-neuronal infection in immunosuppressed patients.

221 nt infection and can cause severe disease in immunosuppressed patients.

222 al evidence of disease affecting >1 organ in immunosuppressed patients.

223 eptotrichia infections have been reported in immunosuppressed patients.

224 course of MGUS or risk profile in long-term immunosuppressed patients.

225 ptides, may be useful for identifying OIS in immunosuppressed patients.

226 s from immunocompetent patients and 59% from immunosuppressed patients.

227 l skin samples from both immunocompetent and immunosuppressed patients.

228 or the prevention and treatment of cancer in immunosuppressed patients.

229 of sunlight-related skin cancer in long-term immunosuppressed patients.

230 uman adenovirus (AdV), a virus that can kill immunosuppressed patients.

231 he markedly increased risk of skin cancer in immunosuppressed patients.

232 d often fatal infections in hospitalized and immunosuppressed patients.

233 causes disease in immunologically naive and immunosuppressed patients.

234 al to prevent post-transplantation cancer in immunosuppressed patients.

235 hat low-virulence strains can cause NSSTI in immunosuppressed patients.

236 is required with regard to TSO treatment in immunosuppressed patients.

237 Low-level responses were detectable in immunosuppressed patients.

238 ll neurons and cortical pyramidal neurons in immunosuppressed people.

239 xt, or possible de-novo infection during the immunosuppressed peritransplant period.

240 hiolitis and a major pathogen in elderly and immunosuppressed persons.

241 directly; however, they may locally activate immunosuppressed phagocytes that elicit the antifungal e

242 ell-specific signaling events underlying the immunosuppressed phenotype in sepsis.

243 overy cohort) identifies individuals with an immunosuppressed phenotype that included features of end

244 ial cells and implanted heterotopically into immunosuppressed pigs whose spleens had been removed can

245 drug toxicity, resistance, and an increasing immunosuppressed population warrant continued research i

246 e treatment of Pneumocystis pneumonia in the immunosuppressed population.

247 ommon opportunistic infection in the diverse immunosuppressed population.

248 immunosuppressed populations, review article, editorial,

249 esvirus infection leads to severe disease in immunosuppressed populations.

250 lus fumigatus is a leading cause of death in immunosuppressed populations.

251 major cause of birth defects and disease in immunosuppressed populations.

252 biquitous herpesvirus that causes disease in immunosuppressed populations.

253 ocompetent rabbits than in pharmacologically immunosuppressed rabbits (treated with weekly injections

254 The protective effect of TSO was lost in immunosuppressed rabbits, where TSO exacerbated colitis.

255 ation, and most often develop de novo in the immunosuppressed recipient or as recurrent malignancy af

256 ential and likelihood of transmission to the immunosuppressed recipient.

257 to reactivate after transplantation into an immunosuppressed recipient.

258 er of anti-Asp f3 antibodies did not protect immunosuppressed recipients from aspergillosis.

259 ld sustained allogeneic islet engraftment in immunosuppressed recipients.

260 but no functional differences compared with immunosuppressed recipients.

261 longer and were more easily tolerized by non-immunosuppressed recipients.

262 During the given time, 230 immunosuppressed renal transplanted men fathered 350 chi

263 lumbar spinal ventral horn in presymptomatic immunosuppressed SOD1(G93A) rats and to assess the prese

264 ctivation was associated with the relatively immunosuppressed SRS1 endotype (p = 0.014) and different

265 shifts in metabolic polarity during the late immunosuppressed stage of human sepsis blood leukocytes

266 or patients on hemodialysis because of their immunosuppressed state and in kidney transplant patients

267 This post-traumatic immunosuppressed state has been attributed to over-expre

268 reases in GCF as a result of CsA usage or an immunosuppressed state irrespective of the severity of i

269 this process is accelerated, resulting in an immunosuppressed state that diminishes the ability of th

270 been proposed that LCMV infection induces an immunosuppressed state within the host, our data show th

271 sive inflammation temporally aligned with an immunosuppressed state, defining a complex clinical scen

272 ce, gammaherpesvirus 68 infection induces an immunosuppressed state, reminiscent of compensatory anti

273 Given their immunosuppressed state, SOT recipients are presumed to b

274 polymicrobial sepsis with progression to an immunosuppressed state.

275 iciency virus (HIV), malnutrition, and other immunosuppressed states.

276 or hyperinflammation by acquiring an M2-like immunosuppressed status that increases the risk of secon

277 ely 35x10(6)) versus vehicle in cyclosporine-immunosuppressed swine with a chronic left anterior desc

278 GxxxG analog both associated with the CP and immunosuppressed T-cells, the AxxxG WT but not the GxxxG

279 cant source of morbidity in neonates and the immunosuppressed that contains many genes that modulate

280 g active therapy or who are otherwise highly immunosuppressed, there is a wider spectrum of etiologie

281 uced (F-LR) platelets occurs in about 18% of immunosuppressed thrombocytopenic hematology/oncology pa

282 gan transplant recipients, who are medically immunosuppressed to prevent graft rejection, have increa

283 ains disproportionately less satisfactory in immunosuppressed transplant and oncology patients.

284 ontrolled by T cell-mediated immunity and in immunosuppressed transplant patients it is associated wi

285 V) remains a major cause of viral disease in immunosuppressed transplant patients.

286 Assays which measure immune function in the immunosuppressed transplant recipient relative to infect

287 In contrast, in immunosuppressed transplant recipients and late-stage AI

288 ing the NK and/or T cell systems, as well as immunosuppressed transplant recipients, handle EBV infec

289 For immunosuppressed transplant recipients, this situation p

290 to infection, an important consideration for immunosuppressed transplant recipients.

291 Immunosuppressed transplanted patients and an immunocomp

292 SRS1 is relatively immunosuppressed, whereas SRS2 is relatively immunocompe

293 Non-neutropenic mice that were immunosuppressed with cortisone acetate and infected wit

294 Delta145 or parental virus into guinea pigs immunosuppressed with cyclophosphamide.

295 Nonsurvivors were immunosuppressed with leukopenia and markedly reduced tu

296 th a history of orthotopic heart transplant, immunosuppressed with low-dose cyclosporine, who present

297 For immunosuppressed women (CD4 cell count, <250 cells/muL),

298 Immunosuppressed Yorkshire pigs were assigned to 1 of 3

299 re delivered by intramyocardial injection to immunosuppressed Yorkshire swine (n = 29) 2 weeks after

300 protocols for optimal growth and rearing of immunosuppressed zebrafish at 37 degrees C; optimized in